Italia markets closed
FTSE MIB
32.665,21 -944,64 (-2,81%) Dow Jones
38.589,16 -57,94 (-0,15%) Nasdaq
17.688,88 +21,32 (+0,12%) Nikkei 225
38.814,56 +94,09 (+0,24%) Petrolio
78,49 -0,13 (-0,17%) Bitcoin EUR
61.685,94 -116,48 (-0,19%)
NBIX Dec 2024 145.000 put
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 10:00AM EDT
| Chiusura precedente | 18,50 |
| Aperto | 18,50 |
| Denaro | 17,60 |
| Domanda | 21,00 |
| Prezzo d'esercizio | 145,00 |
| Scadenza | 2024-12-20 |
| Min-Max giorno | 18,50 - 18,50 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 31 |
GlobeNewswireSosei Heptares’ partner Neurocrine Biosciences Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults
NBI-1117570 is an investigational, oral, muscarinic M1/M4 selective dual agonist discovered by Sosei Heptares that may have the potential to treat neurological and neuropsychiatric conditionsNBI-1117570 is the second compound to advance into clinical development from a portfolio of selective muscarinic receptor agonists licensed by Sosei Heptares to Neurocrine following NBI-1117568, an oral, selective muscarinic M4 receptor agonist, which is in Phase 2 clinical trials as an investigational treat
© 2024 Yahoo. Tutti i diritti riservati.